A retrospective study investigating efficacy of Enzalutamide treatment in patients with metastatic castration resistant prostate cancer by assessing prostate-specific antigen (PSA) at 4 weeks

Trial Profile

A retrospective study investigating efficacy of Enzalutamide treatment in patients with metastatic castration resistant prostate cancer by assessing prostate-specific antigen (PSA) at 4 weeks

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2016

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Apr 2016 New trial record
    • 28 Mar 2016 Results published in the Molecular Diagnosis and Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top